A Pilot Study to Assess the Safety, Efficacy, and PK Profile of a Switch in Antiretroviral Therapy to a RTI Sparing Combination of LPV/r and RAL in Virologically Suppressed HIV-infected Patients

Trial Profile

A Pilot Study to Assess the Safety, Efficacy, and PK Profile of a Switch in Antiretroviral Therapy to a RTI Sparing Combination of LPV/r and RAL in Virologically Suppressed HIV-infected Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms KITE
  • Most Recent Events

    • 16 Mar 2012 Actual end date changed from Jun 2011 to Jan 2011 as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top